Ridgeback Capital Investments adds Trillium Therapeutics (TRIL) to its portfolio

Trillium Therapeutics (TRIL) : Ridgeback Capital Investments added new position in Trillium Therapeutics during the most recent quarter end. The investment management firm now holds 370,537 shares of Trillium Therapeutics which is valued at $3.5 Million , the company said in a statement filed on May 13, 2016 with the SEC.Trillium Therapeutics makes up approximately 28.44% of Ridgeback Capital Investments’s portfolio.

Other Hedge Funds, Including , Sabby Management added TRIL to its portfolio by purchasing 14,137 company shares during the most recent quarter which is valued at $135,432. Trillium Therapeutics makes up approx 0.05% of Sabby Management’s portfolio. Tfs Capital added TRIL to its portfolio by purchasing 14,300 company shares during the most recent quarter which is valued at $136,994. Trillium Therapeutics makes up approx 0.02% of Tfs Capital’s portfolio. Oxford Asset Management added TRIL to its portfolio by purchasing 147,819 company shares during the most recent quarter which is valued at $1.4 Million. Trillium Therapeutics makes up approx 0.05% of Oxford Asset Management’s portfolio. New York State Common Retirement Fund sold out all of its stake in TRIL during the most recent quarter. The investment firm sold 2,727 shares of TRIL which is valued $26,943.Awm Investment Company boosted its stake in TRIL in the latest quarter, The investment management firm added 32,540 additional shares and now holds a total of 239,477 shares of Trillium Therapeutics which is valued at $2.4 Million. Trillium Therapeutics makes up approx 0.51% of Awm Investment Company’s portfolio.

Trillium Therapeutics opened for trading at $10.68 and hit $11.0899 on the upside on Wednesday, eventually ending the session at $11.02, with a gain of 4.45% or 0.47 points. The heightened volatility saw the trading volume jump to 38,621 shares. Company has a market cap of $86 M.

Leave a Reply

Trillium Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Trillium Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.